Research evaluating sublethal doses of spinosyn A and D on Trichoplusia ni caterpillars and their egg parasitoid Trichogramma brassicae, examining impacts on development, fecundity, and parasitoid-host interactions using microCT scanning and molecular tools.
This research investigates how sublethal doses of spinosyn A and spinosyn D, the active insecticidal components of the pesticide Spinosad, affect both pest caterpillars and their natural biological control agents. The study focuses on Trichoplusia ni (cabbage looper) caterpillars and the egg parasitoid Trichogramma brassicae, which is widely used in integrated pest management programs. The goal is to understand whether pesticide residues at non-lethal concentrations can reduce pest fitness while still allowing crop damage, and whether smaller host eggs compromise parasitoid effectiveness.
The research addresses a critical question for sustainable agriculture: how do sublethal pesticide exposures ripple through pest-parasitoid food webs? Understanding these effects helps producers make informed decisions about combining biocontrol agents with pesticide applications, ultimately supporting more effective and environmentally responsible pest management strategies.
Research approach:
Key measurements include:
This is an early-stage research project in the planning and validation phase. The two-year study will support an MSc student at McGill University. The research combines established entomological methods with advanced imaging (microCT) and molecular biology techniques (qRT-PCR). Findings will contribute to evidence-based recommendations for integrated pest management programs that combine parasitoid biocontrol with compatible pesticide use.
McGill University is a comprehensive public research university in Montréal, Québec, known for an international community and a research‑intensive culture. Faculty and industry collaborate through shared core facilities and co‑located labs across downtown and hospital sites, with integration into a major hospital system enabling clinical research and translation. Proximity to Montréal’s established industry clusters and a vibrant innovation district give companies access to talent, pilots, and testbeds. Research is supported by Canada’s Tri‑Agency and the Canada Foundation for Innovation, alongside provincial and philanthropic sources. A dedicated technology transfer office streamlines contracting and IP, supports licensing and sponsored research, and connects partners to startups and entrepreneurship resources.